GlycoSeLect UK Announces the Establishment of a New Research Laboratory in South Tees Bio-Incubator
The South Tees Bio-incubator has been set up to allow early-stage biotechnology and life sciences companies become established and realise potential commercial success, by providing access to specialist facilities, expert advice and shared laboratory space.
A strategic partnership between the South Tees Hospitals NHS Foundation Trust, NHSA (Northern Health Science Alliance) and the CPI (Centre for Process Innovation), it has already welcomed its first tenant – GlycoSeLect UK – into its new home at the Institute for Learning, Research and Innovation at The James Cook University Hospital. GlycoSeLect (UK) Ltd, specialists in the development of glycoprotein separation technology for analysis and manufacturing uses in pharmaceutical companies, announces the establishment of a new laboratory facility in South Tees Bio-incubator.
GlycoSeLect’s vision is to be the leading company in the development and manufacture of glycoprotein analytical and manufacturing products for the life science industries. The UK has a world renowned network of pharmaceutical companies making it an excellent environment in which to further develop and commercialise GlycoSeLect’s innovative RPL technology for glycoprotein separation. The South Tees Bio-Incubator laboratory provides the infrastructure and a contact hub to facilitate product and business development with GlycoSeLect’s UK customers.
The Trust’s Director of Innovation and Consultant Cardiac Surgeon Professor Andrew Owens said:
“It’s now widely acknowledged that research, innovation and entrepreneurship are crucial driving factors for the North East’s long-term efficiency, competitiveness and economic growth and initiatives such as this mean the Trust can develop deep and high value partnerships.”
Dr Hakim Yadi, CEO of the Northern Health Science Alliance, explained:
“The North’s life sciences economy is recognised internationally and already contributes £10.8bn to the UK economy. Projects such as The South Tees bio-incubator build on that recognition helping to drive further jobs, investment and innovations into the North. I am looking forward to working with the South Tees incubator and the CPI on a new model of innovation between our respective organisations.”
Dr Chris Dowle, Director of Future Business in Healthcare at CPI added:
“We are delighted to work with the team at South Tees developing this and a series of other exciting healthcare projects where we can focus our technologists and business experts to help to deliver solutions at the front-line. Because of market demand we have plans to extend bio-incubation facilities here in the Tees Valley to join with other supply chain expertise in projects such as the biotherapeutic factories of the future/new healthcare solutions centre planned for 2018.”
Robert Dunne, CEO of GlycoSeLect, said:
“GlycoSeLect is pleased to establish an analytical applications research laboratory which will enhance interactions with biopharmaceutical and other life science industry companies in the UK. The North East of England has a tremendous reputation for welcoming companies from around the world and nurturing their growth and success which we will leverage. Our team are delighted to continue their connections with the Biologics Unit of CPI following our successful Early Stage Feasibility project supported by an award from InnovateUK. The South Tees Bio-Incubator provides our team with an excellent working environment and facilities needed to grow our business in a renowned medical research campus.”